Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma

  • Cancer Res Commun. 2024 Dec 1;4(12):3165-3179. doi: 10.1158/2767-9764.CRC-24-0382.
Yichi Zhang  1 ,  Marjaana Ojalill  1 ,  Antonia Boyer  1 ,  Xiao Lei Chen  1 ,  Elise Tahon  1 ,  Gaëtan Thivolle Lioux  1 ,  Marvin Xia  1 ,  Maryam Abbas  1 ,  Halime Meryem Soylu  1 ,  Douglas B Flieder  2 ,  Denise C Connolly  2 ,  Alfredo A Molinolo  3 ,  Michael T McHale  1 ,  Dwayne G Stupack  1 ,  David D Schlaepfer  1
Affiliations
  • 1. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, University of California, San Diego, La Jolla, California.
  • 2. Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • 3. Department of Pathology, Moores Cancer Center, University of California San Diego, La Jolla, California.
PMID: 39585085 DOI: 10.1158/2767-9764.CRC-24-0382
Abstract

FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras-Raf-MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated survival signaling may be tumor type- and context-dependent.

Products